Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRCAP21 is a **stimulant- and sugar-free nutraceutical formulation** developed as a dietary supplement for weight management and body recomposition. It incorporates six key constituents, including D-ribose, nicotinamide, alpha glycerol phosphorylcholine, and four other evidence-based botanicals, encapsulated in a Prodosomed® liposomal multilayer structure for sustained and sequential release. The proposed mechanism involves restoring healthy systemic aerobic metabolism, improving oxygen utilization, and enabling efficient cellular waste removal. This approach aims to address multiple biological pathways that contribute to obesity, metabolic inefficiency, diminished hormone functionality, and sluggish metabolism with increased fat storage. TRCAP21 has been evaluated in clinical pilot studies and is currently under double-blind, placebo-controlled investigation for efficacy in improving various anthropometric measurements, body composition, mood, energy, satiety, and sugar cravings[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TRCAP21.